Plain-English translation of NCT07308847 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing a new medical device called the Sphere-360 Catheter paired with the Affera Mapping and Ablation System to treat paroxysmal atrial fibrillation (PAF), a type of irregular heartbeat that comes and goes on its own. The procedure, called pulmonary vein isolation ablation, uses this new device to carefully treat the parts of your heart causing the irregular rhythm. This is a pre-market study, meaning the device is being evaluated before it becomes widely available.
Paroxysmal atrial fibrillation can cause uncomfortable symptoms and increase the risk of serious complications like stroke. Currently available treatments don't work for everyone, so researchers are testing this new device to see if it can safely and effectively eliminate these irregular heartbeats.
If you qualify, you would undergo a cardiac catheter ablation procedure using the new Sphere-360 device and Affera mapping system. The procedure involves inserting a thin catheter through blood vessels to reach your heart and carefully treat the areas causing irregular rhythms. You would attend baseline appointments, the ablation procedure, and multiple follow-up visits over the study period to monitor your heart rhythm and overall health.
AI-generated summary from trial data · Aug 7, 2026 · Not medical advice
United States